142507-59-3

Upstream product

• 6118-51-0 exo-3,6-epoxy-1,2,3,6-tetrahydrophthalic anhydride 

Downstream Products

• 817201-15-3 (2R,3S,4S,5S)-3-(tert-butyldiphenylsilyloxy)methyl-4-methyl-2,5-bis[(p-toluenesulfonyloxy)methyl]-4-methyltetrahydrofuran 
• 817201-21-1 (1S,2S,3R,4R)-2-(tert-butyldiphenylsilyloxy)methyl-3-(p-toluenesulfonyloxy)methyl-7-oxabicyclo[2.2.1]hept-5-ene 
• 817201-03-9 (2S,3S,4S,5R)-3-(tert-butyldiphenylsilyloxy)methyl-4-methyl-2,5-di(2-propenyl)-4-methyltetrahydrofuran 
• 817201-17-5 (1R,6S,7S,8R)-3,4-dibromo-7-(tert-butyldiphenylsilyloxy)methyl-8-methyl-9-oxabicyclo[4.2.1]nonane 
• 817201-16-4 (2R,3S,4S,5S)-3-(tert-butyldiphenylsilyloxy)methyl-4-methyl-2,5-bis(iodomethyl)-4-methyltetrahydrofuran 
• 817201-13-1 (1R,2S,3S,4S,5R,6S)-2-(tert-butyldiphenylsilyloxy)methyl-5,6-dihydroxy-3-methyl-7-oxabicyclo[2.2.1]heptane 
• 817201-14-2 (2R,3S,4S,5S)-3-(tert-butyldiphenylsilyloxy)methyl-2,5-bis(hydroxymethyl)-4-methyltetrahydrofuran 
• 817201-02-8 (1R,6S,7S,8R)-7-(tert-butyldiphenylsilyloxy)methyl-8-methyl-9-oxabicyclo[4.2.1]non-3-ene 
• 816455-25-1 (1S,2S,3R,4R)-2-(tert-butyldiphenylsilyloxy)methyl-3-hydroxymethyl-7-oxabicyclo[2.2.1]hept-5-ene 
• 817201-42-6 (2R,3S,4S,5S)-3-(tert-Butyl-diphenyl-silanyloxymethyl)-4-methyl-tetrahydro-furan-2,5-dicarbaldehyde 
• 817201-18-6 (1R,6S,7S,8R)-7-(tert-butyldiphenylsilyloxy)methyl-8-methyl-9-oxabicyclo[4.2.1]nona-2,4-diene 
• 817201-20-0 (1S,2S,3S,4R)-2-(tert-butyldiphenylsilyloxy)methyl-3-methyl-7-oxabicyclo[2.2.1]hept-5-ene 
• 817201-27-7 (1R,6S,7R,8S)-7-(furan-2-carbonyl)-8-methyl-9-oxabicyclo[4.2.1]nona-2,4-diene 

Relevant academic research and scientific papers

ANTICANCER AGENTS AND PROCESS OF MAKING THEREOF

Provided herein are compositions and processes of making of anticancer compounds useful for cancer treatments. These cyclohexenone compounds show an unexpected result against certain cancer cells compared to their known analogs.

Asymmetric total syntheses of (+)-mycoepoxydiene and related natural product (-)-1893A: Application of one-pot ring-opening/cross/ring-closing metathesis to construct their 9-oxabicyclo[4.2.1]nona-2,4-diene skeleton

The total syntheses of (+)-mycoepoxydiene and (-)-1893A have been completed. The present synthetic strategy features the use of one-pot ring-opening/cross metathesis (ROM/CM) followed by a ring-closing metathesis (RCM) reaction, allowing for the concise construction of the 9-oxabicyclo-[4.2.1]nona-2,4-diene framework from a 7-oxabicyclo[2.2.1]hept-2- ene derivative and 1,3-butadiene. The sequential metathesis product was converted into (+)-mycoepoxydiene through the oxidative rearrangement of a furfuryl alcohol to a pyranone, thereby establishing its absolute stereochemistry. From the common intermediate, a structurally related natural product (-)-1893A was also synthesized via the vinylogous aldol reaction.